Opendoor, Almonty Industries, BioNTech – Great opportunities outside the tech bubble

BioNTech – Positive study data gives wings

Despite the weakness of the overall market, the trading week ended with a 7-day gain of 12.89% to USD 112.89 for the German biotech hopeful. Following the stock's hype during the coronavirus pandemic and its subsequent decline after the vaccine, billions vanished from the order books. However, new hopes are emerging in the field of cancer research.

The Mainz-based company announced a decisive study success with the active ingredient BNT323. In a significant, pivotal Phase 3 study in China, the drug, developed in collaboration with Chinese partner Duality Biologics, outperformed Roche's competing product in a particularly difficult-to-treat form of breast cancer.

Patients lived significantly longer without disease progression, marking a clear success in achieving the study's "primary endpoint". For BioNTech, this represents its first major breakthrough in oncology. Chief Medical Officer Özlem Türeci described the result as a "milestone" in the Company's cancer research.

BNT323 belongs to the class of antibody-drug conjugates (ADC). The principle: an antibody transports a chemotherapeutic substance directly to the tumor cell. This approach spares healthy cells and reduces side effects.

BioNTech is now planning to expand clinical development globally. The drug is already being tested in another international Phase 3 trial in preparation for approval in Europe and the US. In addition, its potential in combination with other therapies is being explored.

Almonty Industries – Attractive opportunity after the setback

The setback suffered by Almonty shares after their successful Nasdaq listing could be a once-in-a-lifetime opportunity for long-term investors. When it comes to securing critical raw materials for the West, tungsten producer Almonty is not only at the top of the US government's list.

Tungsten is considered one of the most important, yet underestimated, raw materials in global competition. It is essential for high-tech, industrial, and defense applications, with China holding a supply monopoly of over 80%. The Western world is looking for reliable sources of supply.

Almonty Industries already operates a stable cash flow asset with the Panasqueira mine in Portugal. However, the real potential lies in the Sangdong mine in South Korea, one of the world's largest and highest-grade tungsten projects outside China, which is set to start production soon. Commissioning is planned for the second half of the year. Analysts estimate that Sangdong could cover over 80% of Western non-Chinese production at full capacity. Its economic viability is further supported by significantly higher ore grades compared to Panasqueira.

Market conditions are playing into Almonty's hands. China's export restrictions and production losses in key mining areas such as Jiangxi and Hunan are exacerbating the global supply deficit. At the same time, prices for concentrates and processed products are rising. The US has classified tungsten as a critical raw material and plans to ban imports from China and Russia starting in 2027 - a move that is expected to provide Almonty with a significant geopolitical tailwind by then at the latest.

The Company is in a solid financial position. Its Nasdaq listing raised USD 90 million, with a further USD 25 million in cash available at the end of the quarter. A purchase agreement with the US Department of Defense, along with minimum price guarantees for tungsten and molybdenum, provides strong planning security. Furthermore, entering downstream processing through its own oxide plant could also significantly increase margins.

Analysts at GBC Research forecast revenues of EUR 212 million for 2027, with a net margin of around 40%. All analysts covering Almonty currently recommend the stock as a "Buy". With a current market capitalization of around CAD 1.34 billion, many market participants see further upside potential, especially following the recent price setback, which dropped from a high of CAD 8.66 to the current level of CAD 5.71.

Opendoor – Meme stock on the rise

The meme hype is picking up again, a sign, at least in the past, that the overall market could be at a turning point. One of these hyped stocks is Opendoor, a US iBuyer company that enables private individuals to sell residential properties quickly by generating instant cash offers online, purchasing properties "as is," organizing necessary repairs, and then reselling them.

Last Thursday, Opendoor shares reached their highest level since August 2022, with a daily gain of over 16% and a price of USD 5.96. The rally is being driven by short squeeze fantasies and the support of prominent investors such as Eric Jackson of EMJ Capital, who sees Opendoor as a "leading cult stock." On social media, he called for the return of co-founder Keith Rabois to the board and announced that he himself would seek a seat on the board. Jackson also caused a stir with his attempt to win rapper Drake as a shareholder.

From a fundamental standpoint, Opendoor reported Q2 revenue of USD 1.6 billion and achieved a positive adjusted EBITDA of USD 23 million, the first since 2022. However, the Company expects figures to decline again in Q3. Leadership changes have also drawn attention: CEO Carrie Wheeler recently stepped down, with Shrisha Radhakrishna now acting as interim CEO. Wheeler's sale of shares worth USD 35 million in the run-up to the rally also drew criticism.

In addition to the focus on artificial intelligence, the return to Nasdaq compliance also helped give the stock new momentum. Nevertheless, 24% of freely tradable shares remain shorted, a factor that could continue to cause extreme price movements. Since the beginning of the year, the share price has risen by over 270%.

BioNTech reported successful study results. The meme hype is driving Opendoor to a new three-year high. Almonty Industries is likely to benefit from US policy and offers an attractive entry point after the setback.